Targeting metastatic melanoma

American Journal of Health-System Pharmacy

Volumn 65, Issue 24 SUPPL. 9, 2008, Pages

  Poust, Jamie ^a  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Dacarbazine; Ipilimumab; Mechanism of action; Melanoma; Neoplasm metastasis; Neoplasm vaccines; Oblimersen; Site of action; Sorafenib; Tremelimumab; Vaccines

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CARBOPLATIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; MELANOMA VACCINE; MESSENGER RNA; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN SERINE KINASE; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; THREONINE; TICILIMUMAB; VITESPEN;

ADJUVANT THERAPY; ADRENAL DISEASE; ANTISENSE THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLITIS; CONFERENCE PAPER; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOLITIS; GENE MUTATION; HEPATITIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; SKIN METASTASIS;

EID: 57649144024     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080461     Document Type: Conference Paper

References (35)

1. Fecher LA, Cummings SD, Keefe MJ et al. Toward a molecular classification of melanoma. J Clin Oncol. 2007; 25:1606-20.
2. Kasper B, D'Hondt V, Vereecken P et al. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol. 2007; 62:16-22.
3. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24:4738-45.
4. Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res. 1999; 59(7 Suppl):1693s-1700s.
5. Klasa RJ, Gillum AM, Klem RE et al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002; 12:193-213.
6. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 2005; 24:165-83.
7. Shinozaki M, Fujimoto A, Morton DL et al. Incidence of B-RAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004; 10:1753-7.
8. Panka DJ, Wang W, Atkins MB et al. The RAF inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006; 66:1611-9.
9. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006; 18:615-21.
10. Flaherty KT, Redlinger M, Schuchter LM et al. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol. 2005; 23:Abstract 3037.
11. Agarwala SS, Keilholz U, Hogg D et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol. 2007; 25(18S):8510.
12. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008; 26:2178-85.
13. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007; 110:2614-27.
14. Wells AD, Walsh MC, Bluestone JA et al. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell energy. J Clin Invest. 2001; 108:895-903.
15. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol. 2005; 23:8968-77.
16. Gomez-Navarro J, Sharma A, Bozon V et al. Dose and schedule selection for the anti-CTLA-4 monoclonal antibody CP-675,206 in patients (pts) with metastatic melanoma. J Clin Oncol. 2006; 24(18 suppl):s460.
17. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043-53.
18. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003; 100:8372-7.
19. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005; 12:1005-16.
20. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12:864-72.
21. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24:2283-9.
22. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007; 12:873-83.
23. Barth A, Hoon DS, Foshag LJ et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 1994; 54:3342-5.
24. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol. 1998; 25:611-22.
25. Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007; 25(June 20 Suppl):8508.
26. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol. 2007; 34:165-72.
27. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol. 2002; 44:81-102.
28. Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol. 2004(Feb); Appendix 1T.
29. Moseley P. Stress proteins and the immune response. Immunopharmacology. 2000; 48:299-302.
30. [No authors listed] Cancer vaccine - Antigenics. BioDrugs. 2002; 16:72-4.
31. Caudill MM, Li Z. HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther. 2001; 1:539-47.
32. Parmiani G, Belli F, Testori A et al. Clinical and immunological results of vaccination with autologous heat-shock protein peptide complex-96 (HSPPC-96) in metastatic melanoma. Proc Am Soc Clin Oncol. 2001; 20:Abstract 1006.
33. Parmiani G. Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma. J Clin Oncol. 2004; 22(July 15 Suppl):7510.
34. Richards J, Testori A, Whitman E et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. J Clin Oncol. 2006; 24(June 20 Suppl):8002.
35. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol. 1997; 14:173-92.